New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan 1 vs Dermorphin

Melanotan 1 vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticSexual Health & Libido
Melanotan 1
Recovery & Repair
Dermorphin
Summary
Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
SubQ
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
0.5–1 mg
Not established for human use; research doses vary widely
Frequency
Daily until desired color achieved, then maintenance
Not established
Key Benefits
  • Induces skin pigmentation/tanning without UV exposure
  • Provides photoprotection in photosensitivity conditions (EPP)
  • FDA-approved for erythropoietic protoporphyria (SCENESSE)
  • Approved in EU for EPP treatment
  • Anti-inflammatory via MC1R
  • Mild libido enhancement
  • Potential skin cancer prevention through melanin protection
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Nausea (especially at higher doses)
  • Facial flushing
  • Fatigue
  • Injection site reactions
  • +3 more
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With